Pharmacists analyze momelotinib's role in treating anemia in myelofibrosis, exploring its place in practice and impact on patient care amidst emerging therapies.
before there is promising news in the fight against alzheimer s. elana lily since it s drug appears to be slowing the progression of that terrible disease. it s been an 18 month clinical trial look at this and found 35% of those showed cognitive decline while 39% were less likely to advance to the next stage about. 47% showed no disease progression a year after treatment. apparently stopping alzheimer s in its tracks. is this too good to be true? dr. janette nesheiwat joins us now. this seems to be an amazing breakthrough. do you have faith in this new drug and what does the new studies show you? hey eric, yes, i do have faith in the student drug. we ve got to see what the phase three trial data outcome is what should be out by the end of next month. some of the study found is about 1700 participants between the ages of c and 85 about 71% of
to treat alzheimer s. the makers of the drug say clinical trials show the drug can slow cognitive decline in patients. there is a risk of swelling and bleeding in the brain. it should only be used for patients in earlier mild stages of the illness. they plan to review phase three trial data soon. the f.d.a. s approval came less than a week after a report found that agency failed to follow its own standards when approving a different alzheimer s drug last year. prince harry and tell all memoir is set to be released tomorrow after it leaked on thursday. a ton of hype around the book. title, spare, which refers to a phrase that harry writes king charles used to refer to harry, his second son, as his spare or backup heir since he already security an heir in harry s older brother. a physical altercation between harry and his brother, william,
and i w alzheimer s drug appears to be the first to slow the progression of decline. it works by removing the plaque from the brain. and the buildup of the naturally occurring protein can block neuro pathways making it a hallmark of alzheimer s. the drug eventually helped reduce the levels and slowed cognitive decline by 27%. that is maybe of the first medication we have that is such a positive result so far. but we have to be cautious about it. while the data is encouraging there, the there were also serious safety concerns in the phase three trial. brain swelling and brain bleeding, things that the fda will evaluate if the drug comes up for approval. number eight mental health. in a cnn kff poll this summer, 90% of adults said they believe that there is a mental health crisis in the united states. and another survey found nearly one in four results age 18 to 44